Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing
Open Access
- 19 June 2025
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 157 (9) , 1898-1911
Abstract
DPYD gene variations are associated with severe fluoropyrimidine toxicity, and an initial 50% dose reduction is widely recommended for heterozygous carriers of relevant DPYD variants, including DPYD*2A, DPYD*13, c.2846A>T, and c.1236G>A. However, there is a high variability in DPD activity between DPYD variant carriers, and a proportion of patients may tolerate higher fluoropyrimidine doses. The aim of this retrospective study was to compare fluoropyrimidine toxicity outcomes and tolerated dose intensities between different DPYD variant carriers that received DPYD genotype‐guided dosing. We identified DPYD variant carriers that received fluoropyrimidine‐based treatment between January 2015 and February 2021 in three Dutch Hospitals. The initial fluoropyrimidine dose was reduced by 25–50% for all heterozygous DPYD variant carriers following the Dutch Pharmacogenetics Working Group guideline. Toxicity outcomes were collected for the first three cycles. From 2112 consecutively DPYD‐genotyped patients, 120 patients with DPYD variants were included. The frequency of overall severe toxicity was 21% for wild types, 27% for heterozygous DPYD variant carriers overall, 19% for c.1236G>A carriers, 38% for c.2846A>T carriers, and 44% for DPYD*2A carriers. Median relative dose intensity for cycles 1–3 was 71% for c.1236G>A carriers, 68% for c.2846A>T carriers, and 52% for DPYD*2A carriers. Despite good fluoropyrimidine tolerance in a large proportion of patients, only 13% of patients underwent dose escalation. Novel studies are highly needed to establish the optimal fluoropyrimidine starting dose for heterozygous carriers of c.1236G>A. After initial dose reduction, dose uptitration based on individual tolerance and therapeutic drug monitoring in all DPYD variant heterozygotes is advised to prevent the risk of underdosing.Keywords
This publication has 51 references indexed in Scilit:
- A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer RegimensClinical Pharmacology & Therapeutics, 2023
- Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapyEuropean Journal of Clinical Pharmacology, 2023
- Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyClinical Pharmacology & Therapeutics, 2022
- PathogenicDPYDVariants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysisInternational Journal of Cancer, 2018
- Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil TherapyClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- DPYDGenotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon CancerJAMA Oncology, 2016
- Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicityInternational Journal of Cancer, 2014
- Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling StrategyClinical Pharmacokinetics, 2012